Video Series

Martin Dietrich, MD, PhD, explains what KRAS G12C mutations in NSCLC are and how common they are within the NSCLC landscape.

Drs Podesta and Brixner discuss possible ways to improve access to PDTs for every party involved—patient, payer, and provider.

Two medical experts relay their ideas on how to better improve the payer-provider relationship surrounding PDT use.

Daniel Culver, DO, details how COVID-19 has impacted the treatment of ILD.

Kristin Highland, MD, and Ryan Haumschild, PharmD, MS, MBA, compare management tools to self-regulation for the best ILD treatment outcome, as well as patient access to nintedanib, pirfenidone, and tocilizumab through special pharmacies.

Drs Richter and Kaufman conclude by discussing future promising developments in RRMM therapy.

Professional experts offer suggestions on how payers can be further educated on RRMM treatment.

Drs Joshua Richter and Jonathan L. Kaufman consider where IMiDs fall in the RRMM treatment landscape in comparison with emerging treatment options, such as bispecific antibodies and CAR T-cell therapy.

Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers.

Dr Paul Noble comments on the role lung transplants play in ILD treatment.

Daniel Culver, DO, concludes the clinical trial discussion by elaborating on Dr Highland’s assessments of the data that support the use of nintedanib, pirfenidone, and tocilizumab when treating IPF, PF-ILD, and SSc-ILD.

Dr Brixner highlights the important factors a payer must look at when determining PDT coverage, and Dr Podesta comments from the provider perspective.

Medical professionals discuss PDT management, from patient satisfaction and clinical outcomes to cost.

Three medical experts highlight unmet needs they routinely run into while treating patients with NSCLC.

Joshua Sabari, MD, provides a breakdown of advanced non-small cell lung cancer (NSCLC) and its actionable mutations.

Two practicing physicians discuss clinical pathways and decision-making tactics used at their respective institutions for RRMM management.

Dr Richter explains which patients would benefit the most from using lenalidomide vs pomalidomide, while Dr Kaufman calls attention to clinical trials that support the use of pomalidomide in RRMM therapy.

Dr Kristin Highland continues the treatment landscape discussion, focusing on systemic sclerosis ILD (SSc-ILD) and clinical trial data that studied therapy options for IPF, PF-ILD, and SSc-ILD.

The panel provides an overview of the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressing fibrosing ILD (PF-ILD).

Dr Arwen Podesta explains her PDT patient selection process and the factors she considers before treatment.

Dr Podesta calls on her experience using PDTs with patients to describe what successes and challenges are common.

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.

Two experts highlight their preferred treatment options for RRMM based on each line of therapy the patient will need.

Drs Kaufman and Richter outline important considerations physicians should be aware of when selecting IMiD therapy for a patient with RRMM.

Arwen Podesta, MD, provides an overview of how PDTs have evolved over the past 6 years since their introduction into the medical world.

Two experts define prescription digital therapeutics (PDTs) and their role in behavioral care therapy.

Dr Jonathan L. Kaufman discusses the role immunomodulatory drugs (IMiDs) play within triplet regimens for patients with RRMM.